News

Under the terms of the agreement, Pharsight stockholders will receive $5.50 in cash for each outstanding share of common stock. The board of directors of Pharsight has unanimously

The study is being conducted under an investigational device exemption by Guy Clifton and other researchers at the University of Texas Health Science Center in Houston, whose institutional

NewLab joins Charles River Biopharmaceutical Services, which provides services to support the development and manufacture of biologics. James Foster, chairman, president and CEO of Charles River, said: “The

Mr Scardina has served on the Millennium board of directors since October 2007. Most recently he was self-employed as an independent consultant after serving as an executive with

Mr Davis joins Abingdon from Santarus Pharmaceuticals where he was senior director of regulatory affairs. Mr Davis, with over 20 years of regulatory experience, has brought both drug

The Pill-Plus adds a third hormone, an androgen, to the normal two hormone (estrogen and progestogen) oral contraceptive to prevent androgen deficiency which often leads to a decrease

In this study, preliminary results indicated that R7128 demonstrated significant short-term antiviral activity in patients who were previous non-responders or relapsers to treatment and was generally safe and

The study involved dosing type 2 diabetes subjects with single doses of 0mg (placebo), 10mg, 15mg, 20mg and 30mg tablets of IN-105 in five separate periods before a

The clinical study is analyzing paraffin embedded tissue samples from over 500 prostate cancer patients who had undergone radical prostatectomy, collected at four major clinical centers in Europe